4-[(2-丁基-6,7-二氯-2-环戊基-2,3-二氢-1-氧代-1H-茚-5-基)氧基]-丁酸 | 82749-70-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 4-[(2-丁基-6,7-二氯-2-环戊基-2,3-二氢-1-氧代-1H-茚-5-基)氧基]-丁酸
• 英文名称: Dcpib
• 英文别名: 4-[(2-butyl-6,7-dichloro-2-cyclopentyl-1-oxo-3H-inden-5-yl)oxy]butanoic acid
• CAS: 82749-70-0
• 化学式: C₂₂H₂₈Cl₂O₄
• 分子量: 427.368
• InChiKey: KHKGTPJPBOQECW-UHFFFAOYSA-N

物化性质

• 沸点：
  593.8±50.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)
• 溶解度：
  不溶于水；乙醇中≥49.8 mg/mL； DMSO 中≥50.8 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

生物活性

DCPIB 是一种选择性、可逆且有效的体积调节性阴离子通道（VRAC）抑制剂，能够电压依赖性激活钾离子通道 TREK1 和 TRAAK，并抑制 TRESK、TASK1 和 TASK3。其 IC50 值分别为 0.14 μM（TRESK）、0.95 μM（TASK1）、50.72 μM（TASK3）。此外，DCPIB 还能同时抑制肿胀激活氯电流 (ICl, swell)，在 CPAE 细胞中的 IC50 值为 4.1 μM。

靶点

• TRESK: 0.14 μM
• TASK1: 0.95 μM
• TASK3: 50.72 μM
• ICl, swell (CPAE cells): 4.1 μM

反应信息

• 作为产物：
  描述：

  2,3-二氯茴香醚 在 aluminum (III) chloride 、 potassium tert-butylate 、 水 、 盐酸二甲胺 、 potassium carbonate 、 溶剂黄146 、 sodium iodide 、 sodium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 59.67h， 生成 4-[(2-丁基-6,7-二氯-2-环戊基-2,3-二氢-1-氧代-1H-茚-5-基)氧基]-丁酸
  参考文献：
  名称：

  Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes

  摘要：

  2型糖尿病与胰岛素抵抗、胰岛β细胞胰岛素分泌受损和非酒精性脂肪性肝病有关。组织特异性的SWELL1消融影响了脂肪、骨骼肌和内皮细胞中的胰岛素信号传导，影响了β细胞的胰岛素分泌和血糖控制。在这里，我们展示了在小鼠和人类糖尿病中，脂肪和β细胞中的I_Cl,SWELL和SWELL1蛋白质被降低。通过结合冷冻电镜、分子对接、药物化学和功能研究，我们定义了一种结构活性关系，以合理设计SWELL1通道抑制剂（DCPIB/SN-401）的活性衍生物，这些衍生物结合SWELL1六聚体复合物，通过SWELL1依赖机制恢复SWELL1蛋白质、质膜转运、信号传导、血糖控制和胰岛素分泌。在体内，SN-401恢复小鼠糖尿病的血糖控制，减少肝脏脂肪变性/损伤，改善胰岛素敏感性和胰岛素分泌。这些发现表明，SWELL1通道调节剂改善了2型糖尿病中依赖SWELL1的全身代谢，代表了糖尿病和非酒精性脂肪性肝病的首个一类治疗方法。

  DOI：

  10.1038/s41467-022-28435-0

文献信息

• [EN] SWELL1-LRRC8 COMPLEX MODULATORS<br/>[FR] MODULATEURS DU COMPLEXE SWELL1-LRRC8
  申请人：UNIV WASHINGTON

  公开号：WO2020252041A1

  公开（公告）日：2020-12-17

  The present invention is directed to various polycyclic compounds and methods of using these compounds to treat a variety of diseases including metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease; cardiovascular diseases such as hypertension and stroke; neurological diseases, male infertility, muscular disorders, and immune disorders.

  本发明涉及各种多环化合物，以及利用这些化合物治疗各种疾病的方法，包括代谢性疾病，如肥胖、糖尿病、非酒精性脂肪肝病；心血管疾病，如高血压和中风；神经系统疾病、男性不育、肌肉疾病和免疫系统疾病。
• Treatment of brain injury due to gray matter edema with (indanyloxy)
  申请人：Merck & Co., Inc.

  公开号：US04465850A1

  公开（公告）日：1984-08-14

  The invention relates to the treatment and prevention of injury to the gray matter of the brain and to the spinal chord due to accidents, ischemic stroke, cardiac arrest, arrested breathing, Reye's syndrome and hydrocephalus by the administration of (indanyloxy)butanoic acids, their derivatives, analogs and salts thereof.

  本发明涉及通过给予（indanyloxy）丁酸、其衍生物、类似物和盐来治疗和预防由事故、缺血性中风、心脏停止、呼吸停止、Reye综合症和脑积水引起的大脑灰质和脊髓损伤。
• Agents for the treatment of brain injury. 1. (Aryloxy)alkanoic acids
  作者：E. J. Cragoe、N. P. Gould、O. W. Woltersdorf、C. Ziegler、R. S. Bourke、L. R. Nelson、H. K. Kimelberg、J. B. Waldman、A. J. Popp、N. Sedransk

  DOI：10.1021/jm00347a017

  日期：1982.5

  Blunt and ischemic injuries of the brain have been shown to result in swelling that is predominantly limited to a single cell type, the astrocyte, within the complex cellular mosiac of cerebral gray matter. Evaluation of various diuretic (aryloxy)acetic acids in vitro using incubating cat brain slices and primary astrocyte cultures identified compounds with marked ability to inhibit brain tissue swelling. Some of the compounds significantly reduced the mortality and morbidity following acceleration/deceleration brain injury in anesthesized cats. A variety of (indanyloxy)alkanoic acids were synthesized which were analogous to the dually active (indanyloxy)acetic acids. Some of the 4-(indanyloxy)butanoic acids were found to be devoid of diuretic activity but to possess equal or greater activity than the dually active compounds in the in vitro and in vivo brain assays. Selected examples from both the (indanyloxy)acetic and 4-(indanyloxy)butanoic acid series showed marked chiral effects, with one enantiomer generally exhibiting a much greater activity than the other. A clinical study of severely head-injured patients treated with ethacrynic acid demonstrated a significantly improved outcome when compared to controls. These data suggest a clinical advantage for the nondiuretic (aryloxy)alkanoic acids which possess in vitro and in vivo activities in the cat brain assays that are comparable or superior to dually active compounds.
• CRAGOE, E. J. ,, JR;GOULD, N. P.;WOLTERSDORF, O. W. ,, JR;ZIEGLER, C., J. MED. CHEM., 1982, 25, N 5, 567-579
  作者：CRAGOE, E. J. ,, JR、GOULD, N. P.、WOLTERSDORF, O. W. ,, JR、ZIEGLER, C.

  DOI：——

  日期：——
• Pharmaceutical compositions containing 4-((6,7-Dihalogen-2,3-dihydro-1-oxo-1H-inden-5-yl)-oxy) butanoic acid compounds
  申请人：Merck & Co., Inc.

  公开号：EP0047011B1

  公开（公告）日：1985-06-19